• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[Radiotherapy plus durvalumab for the treatment of locally advanced non-small cell lung cancer-The DOLPHIN trial].

作者信息

Trommer Maike

机构信息

Klinik und Poliklinik für Radioonkologie, Cyberknife- und Strahlentherapie, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), Medizinische Fakultät und Universitätsklinikum Köln, Köln, Deutschland.

Department of Radiation Oncology, Olivia Newton-John Cancer Wellness and Research Centre, Austin Health, Melbourne, Australien.

出版信息

Strahlenther Onkol. 2024 Jul;200(7):646-648. doi: 10.1007/s00066-024-02231-9. Epub 2024 Apr 18.

DOI:10.1007/s00066-024-02231-9
PMID:38635049
Abstract
摘要

相似文献

1
[Radiotherapy plus durvalumab for the treatment of locally advanced non-small cell lung cancer-The DOLPHIN trial].[放疗联合度伐利尤单抗治疗局部晚期非小细胞肺癌——海豚试验]
Strahlenther Onkol. 2024 Jul;200(7):646-648. doi: 10.1007/s00066-024-02231-9. Epub 2024 Apr 18.
2
Optimal Duration of Consolidation Durvalumab Following Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer: A Multi-institutional Retrospective Study.III期非小细胞肺癌放化疗后巩固性度伐利尤单抗的最佳疗程：一项多机构回顾性研究
Target Oncol. 2025 Jan;20(1):161-169. doi: 10.1007/s11523-024-01105-5. Epub 2024 Nov 7.
3
Durvalumab after concurrent chemoradiotherapy for sensitizing epidermal growth factor receptor-mutant stage III non-small cell lung cancer: A Japanese Real-World data analysis.同步放化疗后使用度伐鲁单抗治疗表皮生长因子受体突变的 III 期非小细胞肺癌的敏感性：一项日本真实世界数据分析。
Lung Cancer. 2025 Jul;205:108597. doi: 10.1016/j.lungcan.2025.108597. Epub 2025 May 27.
4
A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer patients with PS 2 up to 74 years old and patients with PS 0 or 1 from 75 years: NEJ039A (trial in progress).一项 II 期研究，每日卡铂联合放疗后序贯度伐利尤单抗用于 PS 2 评分高达 74 岁的 III 期非小细胞肺癌患者，以及 PS 0 或 1、年龄 75 岁以上的患者：NEJ039A（正在进行的试验）。
BMC Cancer. 2020 Oct 6;20(1):961. doi: 10.1186/s12885-020-07406-y.
5
Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non-Small Cell Lung Cancer: Update From the COAST Randomized Clinical Trial.度伐利尤单抗单药或联合新型药物治疗不可切除的 III 期非小细胞肺癌：COAST 随机临床试验的最新进展
JAMA Netw Open. 2025 Jul 1;8(7):e2518440. doi: 10.1001/jamanetworkopen.2025.18440.
6
Isolated nodal failure in stage III non-small-cell lung cancer after proton therapy with or without durvalumab.在接受质子治疗联合或不联合度伐利尤单抗的 III 期非小细胞肺癌中出现的孤立性淋巴结失败。
Radiother Oncol. 2025 Aug;209:110990. doi: 10.1016/j.radonc.2025.110990. Epub 2025 Jun 18.
7
Durvalumab after sequential chemoradiotherapy in unresectable stage III non-small-cell lung cancer-final analysis from the phase II PACIFIC-6 trial.不可切除的 III 期非小细胞肺癌序贯放化疗后使用度伐鲁单抗——II 期 PACIFIC-6 试验的最终分析
ESMO Open. 2025 Jun;10(6):105071. doi: 10.1016/j.esmoop.2025.105071. Epub 2025 May 27.
8
Real-world outcomes of subsequent treatment strategies after durvalumab consolidation in stage III unresectable non-small cell lung cancer.度伐利尤单抗巩固治疗后 III 期不可切除非小细胞肺癌后续治疗策略的真实世界疗效
Lung Cancer. 2025 Jun;204:108576. doi: 10.1016/j.lungcan.2025.108576. Epub 2025 May 3.
9
Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study.durvalumab 联合放化疗治疗不可切除 III 期非小细胞肺癌（PACIFIC）患者的报告结果：一项随机、对照、III 期临床研究。
Lancet Oncol. 2019 Dec;20(12):1670-1680. doi: 10.1016/S1470-2045(19)30519-4. Epub 2019 Oct 7.
10
Concerning Safety and Efficacy of Concurrent and Consolidative Durvalumab With Thoracic Radiation Therapy in PDL1-Unselected Stage III Non-Small Cell Lung Cancer: Brief Report.度伐利尤单抗同步及巩固治疗联合胸部放疗用于PDL1未筛选的Ⅲ期非小细胞肺癌的安全性和疗效：简要报告
Int J Radiat Oncol Biol Phys. 2025 Jan 1;121(1):68-74. doi: 10.1016/j.ijrobp.2024.07.2333. Epub 2024 Aug 13.

本文引用的文献

1
Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Phase 2 Nonrandomized Controlled Trial.度伐利尤单抗联合同期放疗治疗局部晚期非小细胞肺癌：DOLPHIN 期 2 非随机对照试验。
JAMA Oncol. 2023 Nov 1;9(11):1505-1513. doi: 10.1001/jamaoncol.2023.3309.
2
Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial.立体定向消融放疗联合或不联合免疫治疗早期或孤立性肺实质复发性淋巴结阴性非小细胞肺癌：一项开放标签、随机、2 期临床试验。
Lancet. 2023 Sep 9;402(10405):871-881. doi: 10.1016/S0140-6736(23)01384-3. Epub 2023 Jul 18.
3
Safety and efficacy of radiotherapy/chemoradiotherapy combined with immune checkpoint inhibitors for non-small cell lung cancer: A systematic review and meta-analysis.
放疗/放化疗联合免疫检查点抑制剂治疗非小细胞肺癌的安全性和有效性：系统评价和荟萃分析。
Front Immunol. 2023 Mar 13;14:1065510. doi: 10.3389/fimmu.2023.1065510. eCollection 2023.
4
Radiotherapy induces responses of lung cancer to CTLA-4 blockade.放疗诱导肺癌对 CTLA-4 阻断的反应。
Nat Med. 2018 Dec;24(12):1845-1851. doi: 10.1038/s41591-018-0232-2. Epub 2018 Nov 5.
5
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.Durvalumab 用于 III 期非小细胞肺癌放化疗后的治疗。
N Engl J Med. 2017 Nov 16;377(20):1919-1929. doi: 10.1056/NEJMoa1709937. Epub 2017 Sep 8.
6
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.既往放疗与帕博利珠单抗治疗非小细胞肺癌的临床活性及毒性：KEYNOTE-001 1期试验的二次分析
Lancet Oncol. 2017 Jul;18(7):895-903. doi: 10.1016/S1470-2045(17)30380-7. Epub 2017 May 24.